These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34734967)

  • 21. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
    Madison R; Schrock AB; Castellanos E; Gregg JP; Snider J; Ali SM; Miller VA; Singal G; Alexander BM; Venstrom JM; Chung JH
    Lung Cancer; 2020 Oct; 148():69-78. PubMed ID: 32823229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
    Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
    Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
    J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parallel comparison and combining effect of radiomic and emerging genomic data for prognostic stratification of non-small cell lung carcinoma patients.
    Kim KH; Kim J; Park H; Kim H; Lee SH; Sohn I; Lee HY; Park WY
    Thorac Cancer; 2020 Sep; 11(9):2542-2551. PubMed ID: 32700470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
    Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-Saccà M
    J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for
    Pasello G; Vicario G; Zustovich F; Oniga F; Gori S; Rosetti F; Bonetti A; Favaretto A; Toso S; Redelotti R; Santo A; Bernardi D; Giovanis P; Oliani C; Calvetti L; Gatti C; Palazzolo G; Baretta Z; Bortolami A; Bonanno L; Basso M; Menis J; Corte DD; Frega S; Guarneri V; Conte P;
    Oncologist; 2019 Jun; 24(6):e318-e326. PubMed ID: 30846513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Broad Genomic Testing in NSCLC: No Survival Benefit?
    Cancer Discov; 2018 Oct; 8(10):1201. PubMed ID: 30171013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
    Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
    Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NCC-AUC: an AUC optimization method to identify multi-biomarker panel for cancer prognosis from genomic and clinical data.
    Zou M; Liu Z; Zhang XS; Wang Y
    Bioinformatics; 2015 Oct; 31(20):3330-8. PubMed ID: 26092859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
    BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model.
    Mitra R; Lee J; Jo J; Milani M; McClintick JN; Edenberg HJ; Kesler KA; Rieger KM; Badve S; Cummings OW; Mohiuddin A; Thomas DG; Luo X; Juliar BE; Li L; Mesaros C; Blair IA; Srirangam A; Kratzke RA; McDonald CJ; Kim J; Potter DA
    Clin Cancer Res; 2011 May; 17(9):2934-46. PubMed ID: 21242119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prediction model for lung cancer diagnosis that integrates genomic and clinical features.
    Beane J; Sebastiani P; Whitfield TH; Steiling K; Dumas YM; Lenburg ME; Spira A
    Cancer Prev Res (Phila); 2008 Jun; 1(1):56-64. PubMed ID: 19138936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The project data sphere initiative: accelerating cancer research by sharing data.
    Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
    Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.
    Lu Y; Lemon W; Liu PY; Yi Y; Morrison C; Yang P; Sun Z; Szoke J; Gerald WL; Watson M; Govindan R; You M
    PLoS Med; 2006 Dec; 3(12):e467. PubMed ID: 17194181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development.
    Liu H; Kho AT; Kohane IS; Sun Y
    PLoS Med; 2006 Jul; 3(7):e232. PubMed ID: 16800721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elucidating Analytic Bias Due to Informative Cohort Entry in Cancer Clinico-genomic Datasets.
    Kehl KL; Uno H; Gusev A; Groha S; Brown S; Lavery JA; Schrag D; Panageas KS
    Cancer Epidemiol Biomarkers Prev; 2023 Mar; 32(3):344-352. PubMed ID: 36626408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.
    Pacheco JM; Gao D; Smith D; Purcell T; Hancock M; Bunn P; Robin T; Liu A; Karam S; Gaspar L; Kavanagh B; Rusthoven C; Aisner D; Doebele R; Camidge DR
    J Thorac Oncol; 2019 Apr; 14(4):691-700. PubMed ID: 30599201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.